# AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database

> **NCT06548152** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 120 (estimated)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06548152
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-28
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06548152

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06548152, "AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06548152. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*